Novartis Battling Legal Fight In India over Patent Right
Novartis is fighting a legal battle in India over a patent law. The law often described as Section 3d was formed to do away with the practice of patent monopolies on medications. The law was formed in accordance to the international trade rule.
Under the law, Novartis can't be provided with patent in India. The patent right of Glavic, blood cancer treatment drug, was denied to Novartis in 2006. However, this time, Novartis is all set to get its right. If Novartis wins the battle then in the coming years, the cost effective cancer medicine, Glavic, also popular as Imatinib will not be easily accessible as it is right now.
The victory of Novartis, will force India to grant more patents, in the future. The Executive Director of MSF's Access Campaign, Dr. Manica Balasegaram said, "Because India is the developing world's pharmacy, the consequences of this case stretch far beyond the country's borders. Novartis's legal actions are a direct threat to the lifeline for millions of people in developing countries".
The trail over the case will be held for months unless and until a decision has been taken.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Plug-in cars’ share grows to 32% in Netherlands in September 2021
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids